| Completed | Pharmacokinetics, Safety and Tolerability of ITF2357 in Participants With Chronic Hepatic Impairment and With Hepatic Impairment | Phase 1 | 2025-05-28 |
| Recruiting | Pharmacokinetics and Safety of Givinostat in DMD Patients Ages From at Least 2 Years to Less Then 6 Years Old Duchenne Muscular Dystrophy | Phase 2 | 2025-01-02 |
| Recruiting | Study on Efficacy and Safety of Givinostat Versus Hydroxyurea in Patients With Polycythemia Vera Polycythemia Vera | Phase 3 | 2024-03-26 |
| Recruiting | Efficacy, Safety and Tolerability of Givinostat in Non-ambulant Patients With Duchenne Muscular Dystrophy Duchenne Muscular Dystrophy | Phase 3 | 2024-02-19 |
| Unknown | A Multicentre, Prospective, Open-label, Non-comparative Study Contraception | Phase 4 | 2023-07-20 |
| Completed | Multicenter Prospective Real-world Observational Study to Evaluate the Effectiveness of Phlebotonics, as Conse Hemorrhoidal Disease | — | 2023-04-05 |
| Completed | Givinostat and Metabolites Pharmacokinetics in Urine and Plasma (Part 3) Drug Drug Interaction | Phase 1 | 2022-03-21 |
| Completed | The Potential of Givinostat as DDI Victim in Co-administration P-gp Inhibitor (Part 2) Drug Drug Interaction | Phase 1 | 2022-03-21 |
| Completed | Perpetrator DDI Potential of Givinostat as Inhibitor and Inducer of CYP3A and P-gp Activity Drug-Drug Interaction, Heathy Volunteer | Phase 1 | 2022-03-21 |
| Unknown | Prevalence And Burden Of Nausea And Vomiting In Pregnant Women Nausea Gravidarum, Vomiting of Pregnancy | — | 2021-10-04 |
| Completed | Placebo-Corrected Effects of Therapeutic Dose (100 mg) and Supratherapeutic Dose (300 mg) of ITF2357 (Givinost Duchenne and Becker Muscular Dystrophy, Polycytemia Vera | Phase 1 | 2021-04-13 |
| Completed | Open Non-Comparative Clinical Trial Study To Evaluate The Performance And Safety Of Ainara® Vaginal Disease | N/A | 2019-09-20 |
| Completed | Post Marketing Follow Up Study To Evaluate Performance Safety Quality of Menopausal Transition Women Treated W Vaginal Disease | N/A | 2019-06-27 |
| Completed | Clinical Trial Study To Evaluate The Performance And Safety Of Ainara® Vaginal Disease | N/A | 2019-04-11 |
| Completed | Open Non-Comparative Study To Evaluate Administration Of a New Nutraceutical Sleep Disorder | N/A | 2018-12-27 |
| Completed | Clinical Study to Evaluate the Efficacy and Safety of Givinostat in Ambulant Patients With Becker Muscular Dys Becker Muscular Dystrophy | Phase 2 | 2018-01-09 |
| Recruiting | Givinostat in Duchenne's Muscular Dystrophy Long-term Safety and Tolerability Study Duchenne Muscular Dystrophy | Phase 2 / Phase 3 | 2017-10-24 |
| Completed | Clinical Study to Evaluate the Efficacy and Safety of Givinostat in Ambulant Patients With Duchenne Muscular D Duchenne Muscular Dystrophy | Phase 3 | 2017-06-06 |
| Completed | Phase II Study With ITF2984 in Acromegalic Patients Acromegaly | Phase 2 | 2014-04-01 |
| Completed | A Two-part Study to Assess the Safety and Preliminary Efficacy of Givinostat in Patients With Polycythemia Ver Polycythemia Vera | Phase 1 / Phase 2 | 2013-10-01 |
| Completed | A Two Part Phase 1, Repeated Doses and Continuous Infusion Study With ITF2984 in Healthy Volunteers Healthy | Phase 1 | 2013-05-01 |
| Completed | A Study to Assess Safety/Tolerability, pk, Effects on Histology, Clinical Parameters of Givinostat in Children Duchenne Muscular Dystrophy (DMD) | Phase 1 / Phase 2 | 2013-04-01 |
| Active Not Recruiting | Long-term Study Evaluating the Effect of Givinostat in Patients With Chronic Myeloproliferative Neoplasms Chronic Myeloproliferative Neoplasms | Phase 2 | 2013-03-01 |
| Completed | ITF2984 Repeated Doses Study in Healthy Volunteers Healthy Male Volunteers | Phase 1 | 2012-01-01 |
| Terminated | Open-Label Extension of the Dose Finding Study (DSC/08/2357/36) in Patients With Poly Juvenile Idiopathic Arth Juvenile Idiopathic Arthritis | N/A | 2011-12-28 |
| Terminated | Efficacy and Safety Dose Finding Study of Givinostat to Treat Polyarticular Course Juvenile Idiopathic Arthrit Polyarticular Course Juvenile Idiopathic Arthritis | Phase 2 | 2010-10-01 |
| Completed | Phase II Study of GIVINOSTAT (ITF2357) in Combination With Hydroxyurea in Polycythemia Vera Polycythemia Vera | Phase 2 | 2009-06-01 |
| Terminated | Phase II Clinical Trial of ITF2357 In Patients With Relapsed/Refractory Multiple Myeloma Multiple Myeloma | Phase 2 | 2008-10-01 |
| Terminated | Phase II Study of Histone-deacetylase Inhibitor ITF2357 in Refractory/Relapsed Lymphocytic Leukemia Chronic Lymphocytic Leukemia | Phase 2 | 2008-02-01 |
| Completed | Trial of the Histone-Deacetylase Inhibitor ITF2357 Followed by Mechlorethamine in Relapsed/Refractory Hodgkin' Hodgkin's Lymphoma | Phase 1 / Phase 2 | 2008-02-01 |
| Completed | Phase IIA Study of the HDAC Inhibitor ITF2357 in Patients With JAK-2 V617F Positive Chronic Myeloproliferative Myeloproliferative Diseases | Phase 2 | 2007-12-01 |
| Terminated | Effect of ITF2357 on Mucosal Healing in Patients With Moderate-to-severe Active Crohn's Disease Crohn's Disease | Phase 1 / Phase 2 | 2007-10-22 |
| Terminated | phII Study of an HDAC Inhibitor in Very High-risk Relapsed/Refractory Hodgkin's Lymphoma Patients Hodgkin's Lymphoma | Phase 1 / Phase 2 | 2007-05-01 |
| Completed | Open Label, Multicentre Trial to Assess Safety and Efficacy of ITF2357 in Active Systemic Juvenile Idiopathic Active Systemic, Onset Juvenile Idiopathic Arthritis | Phase 2 | 2006-09-12 |
| Completed | Prevention of Venous and Arterial Thromboembolism, in Cancer Patients Undergoing Chemotherapy, With a Low Mole Advanced Cancer, Metastatic Cancer | Phase 3 | 2003-10-01 |